Pharmacological treatment of tic disorders and Tourette Syndrome.
The present review gives an overview of current pharmacological treatment options of tic disorders and Tourette Syndrome (TS). After a short summary on phenomenology, clinical course and comorbid conditions we review indications for pharmacological treatment in detail. Unfortunately, standardized and large enough drug trials in TS patients fulfilling evidence based medicine standards are still scarce. Treatment decisions are often guided by individual needs and personal experience of treating clinicians. The present recommendations for pharmacological tic treatment are therefore based on both scientific evidence and expert opinion. As first-line treatment of tics risperidone (best evidence level for atypical antipsychotics) or tiapride (largest clinical experience in Europe and low rate of adverse reactions) are recommended. Aripiprazole (still limited but promising data with low risk for adverse reactions) and pimozide (best evidence of the typical antipsychotics) are agents of second choice. In TS patients with comorbid attention deficit hyperactivity disorder (ADHD) atomoxetine, stimulants or clonidine should be considered, or, if tics are severe, a combination of stimulants and risperidone. When mild to moderate tics are associated with obsessive-compulsive symptoms, depression or anxiety sulpiride monotherapy can be helpful. In more severe cases the combination of risperidone and a selective serotonin reuptake inhibitor should be given. In summary, further studies, particularly randomized, double-blind, placebo-controlled trials including larger and/or more homogenous patient groups over longer periods are urgently needed to enhance the scientific basis for drug treatment in tic disorders. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.
Department of Child and Adolescent Psychiatry, University of Technology Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. veit.roessner@uniklinikum-dresden.de
Veit
V
Roessner
Katja
K
Schoenefeld
Judith
J
Buse
Stephan
S
Bender
Stefan
S
Ehrlich
Alexander
A
Münchau
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D010868:Pimozide / Q000627:therapeutic use*; D011437:Propylamines / Q000627:therapeutic use; D018967:Risperidone / Q000627:therapeutic use*; D063325:Tiapride Hydrochloride / Q000627:therapeutic use*; D013981:Tic Disorders / Q000150:complications / Q000188:drug therapy*; D005879:Tourette Syndrome / Q000150:complications / Q000188:drug therapy*
D018759:Adrenergic Uptake Inhibitors; D018492:Dopamine Antagonists; D011437:Propylamines; D010868:Pimozide; D063325:Tiapride Hydrochloride; D000069445:Atomoxetine Hydrochloride; D018967:Risperidone